Legal Opinion
In Re: MYLAN N.V. SECURITIES LITIGATION
District Court, S.D. New York
Decided April 6, 2020No. 1:16-cv-07926Unknown
1Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE MYLAN N.V. SECURITIES LITIGATION 16-CV-7926 (JPO) OPINION AND ORDER J. PAUL OETKEN, District Judge: A group of plaintiffs brings this putative securities class action against the drug manufacturer Mylan N.V. and several of its officers (collectively, “Mylan”), in connection with the alleged misclassification of the EpiPen, a rebate scheme involving the EpiPen, and anticompetitive activity with respect to various generic drugs. On March 29, 2019, this Court granted in part and denied in part Mylan’s motion to dismiss the prior…
2Cases cited19 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Tellabs, Inc. v. Makor Issues & Rights, Ltd.Supreme Court of the United States · 2007
- Novak v. KasaksCourt of Appeals for the Second Circuit · 2000
- Emergent Capital Investment Management, LLC v. Stonepath Group, Inc., Previously Known as Net Value Holdings, Inc., Andrew Panzo and Lee HansenCourt of Appeals for the Second Circuit · 2003
14 more not listed; retrieve them via the Exa API.